A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

Investigator: Bincy Abraham, MD

Study Coordinator:

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03466411

Phone:

Protocol Number: Pro00020639

Description

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.
More to Explore